The DOI matches its Crossref record; 330 of the 334 references it cites were found in a registry or an index.
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Open accessAbstract
Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. In addition, novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, and viral therapies will be reviewed, as well as the current challenges and future directions for research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For this patient population, there is currently no efficacious treatment option available [4].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The current standard of care for GBM includes surgical resection and post-surgery radiotherapy with or without temozolomide (TMZ) chemotherapy [4, 5].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Despite standard of care treatment, GBM recurrence is inevitable and there is no agreed salvage therapy post-recurrence [4, 5].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationThe 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella‐Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,703
Ostrom, Q. T., Gittleman, H. R., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz‐Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 12,063
Self-citationStupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., TAPHOORN, M. J. B., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Bélanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,980
Self-citationComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-citationGlioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,517
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Research works printed but not linked: 3
- World Health Organization., 2016, Histological Classification of Tumors of The Central Nervous System
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), 2019, Central Nervus System Cancers
- Chang, 2019, Neoplasms of the central nervous system., 1568
Cited by
Sorted by citations
Items 801–900 of 1,000
Jahouri, S., Montermini, L., Tawil, N., Jalali, M., Garzia, L., Jabado, N., & Rak, J. W. (2026) · Journal of Extracellular Biology · doi:10.1002/jex2.70152 · Cited by 2
Gao, H., You, G., Huang, J., Lin, Y., Huang, J.-M., Liang, R., & Lin, C. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03905-0 · Cited by 2
GaLNet: Weakly-Supervised Learning for Evidence-Based Tumor Grading and Localization in MR Imaging
Ding, T., Zhang, Z., Yan, J., Sun, Q., Zhao, Y., & Li, Z. (2021) · Communications in computer and information science · doi:10.1007/978-981-16-1194-0_22 · Cited by 2
Chatterjee, A., Bhadane, M., Manjali, J. J., Dasgupta, A., Epari, S., Sahay, A., Patil, V. M., Moiyadi, A. V., Shetty, P. M., & Gupta, T. (2022) · World Neurosurgery · doi:10.1016/j.wneu.2022.02.059 · Cited by 2
Identification and verification of the temozolomide resistance feature gene DACH1 in gliomas
Gu, Q., Li, L., Yao, J., Dong, F.-Y., Gan, Y., Zhou, S., Wang, X., & Wang, X.-F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1120103 · Cited by 2
Park, C., & Chang, J. H. (2023) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2023.0046 · Cited by 2
“The criterion of 40 years of age, which defines the risk group for low-grade glioma, is widely accepted by many other neuro-oncology societies 15,29,31) .”
Tumour-treating fields for high-grade glioma
McKinnon, C., Anzak, A., Wahedi, A., Cook, J. A., & Plaha, P. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014979 · Cited by 2
Silva-Pavez, E., & Urra, H. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101777 · Cited by 2
“While valuable, adjuvant therapies like radiation and chemotherapy provide only marginal increases in overall survival due to the tumor ’ s adaptive resistance mechanisms [2].”
BackgroundDespotović, A., Janjetović, K., Zogovic, N. S., & Tovilović-Kovačević, G. (2023) · Biomedicines · doi:10.3390/biomedicines11102652 · Cited by 2
“This remarkably poor prognosis is a result of the highly invasive GBM nature and development of radio-and chemo-resistance due mostly to numerous genetic alterations and deregulated signaling pathways [2,3].”
BackgroundCalubayan, J. M., & Opinaldo, P. V. (2023) · Cureus · doi:10.7759/cureus.48915 · Cited by 2
Treatment of glioblastoma in Greenlandic patients
Frandsen, S., Pedersen, A. J., Gredal, O., Møller, S., Geisler, U. W., & Nørøxe, D. S. (2023) · International Journal of Circumpolar Health · doi:10.1080/22423982.2023.2285077 · Cited by 2
Chen, Y., Ma, J., Gao, Q., Gai, Y., Sun, Y., & Wang, M. (2024) · Clinics · doi:10.1016/j.clinsp.2024.100329 · Cited by 2
Tawil, N., Adnani, L., & Rak, J. W. (2024) · Bleeding Thrombosis and Vascular Biology · doi:10.4081/btvb.2024.109 · Cited by 2
Zhang, G., Tai, P., Fang, J., Wang, Z., Yu, R., Yin, Z., & Cao, K. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34526 · Cited by 3
Mitobe, Y., Suzuki, S., Nakamura, K., Nakagawa-Saito, Y., Takenouchi, S., Togashi, K., Sugai, A., Sonoda, Y., Kitanaka, C., & Okada, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179473 · Cited by 2
“In contrast, radiation therapy is frequently employed for the treatment of intracranial malignancies in routine practice [5,9].”
BackgroundIn situ optical feedback in brain tumor biopsy: A multiparametric analysis
Klint, E., Richter, J., Milos, P., Hallbeck, M., & Wårdell, K. (2024) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdae175 · Cited by 2
Sharma, S., Roy, R., Vartak, A., Sen, E., & Sk, U. H. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107998 · Cited by 2
PLGA Polymers and Doxorubicin for the Treatment of Malignant Gliomas in Adults: An Overview
Kudelkina, V. V., Gerasimov, A. D., Kosyreva, A. M., Алексеева, А. И., & Makarova, O. V. (2025) · The Open Medicinal Chemistry Journal · doi:10.2174/0118741045346445250111104531 · Cited by 2
Yi, G., Zhang, H.-Y., Que, T., Qu, S., Li, Z., Qi, S., Feng, W.-Y., & Huang, G. (2025) · European journal of medical research · doi:10.1186/s40001-025-02306-y · Cited by 2
“However, despite receiving standard therapy for GBM, the 5-year overall survival rate remains dismal at a mere 6.8% [4, 5].”
InfluentialChallenges and Emerging Strategies of Immunotherapy for Glioblastoma
Mao, M., Yao, L., Ma, X., & Xie, H. (2025) · ChemBioChem · doi:10.1002/cbic.202400848 · Cited by 2
Jiang, L.-W., Li, Z., Ji, X., Jiang, T., Wang, X., & Weng, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-88970-w · Cited by 2
Chiranth, S., Fougner, V., Christensen, I. J., Trip, A. K., Christiansen, T., Nørøxe, D. S., Yde, C. W., Berthelsen, A. K., Hasselbalch, B., Lassen, U., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf092 · Cited by 2
RGN6024 Is a Brain-Penetrant, Small-Molecule Tubulin Destabilizer for the Treatment of Glioblastoma
Patrón, L. A., Yeoman, H., Ramos, J., Risinger, A. L., Gokhale, V. M., & Suzuki, T. C. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-1208 · Cited by 2
Lu, J., Zhang, Z., Zhong, S., Deng, D., Yang, W., Wu, S., Cheng, Y., Bai, Y., & Mou, Y. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s521075 · Cited by 2
Caro, C., Arias‐Ramos, N., Urbano‐Gámez, J. D., González-Alday, R., López‐Larrubia, P., & García‐Martín, M. L. (2025) · Scientific Reports · doi:10.1038/s41598-025-06684-5 · Cited by 2
High Expression of PDIA4 Contributes to Poor Prognosis in Glioma
Liu, Y., He, H., Zou, Y., Feng, J., Liu, H., Gao, P., Lu, W., Zhao, Y., & Ma, H. (2025) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.70042 · Cited by 2
Translational advancements in tumor vaccine therapies for glioblastomas
Jha, R., Spanehl, L., Chen, J., Gessler, F. A., Arnaout, O. M., Valdes, P. A., Choi, B. D., Peruzzi, P., Bernstock, J. D., & Chiocca, E. A. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf051 · Cited by 2
“5,6 However, (Gliadel) is costly and has shown high complication rates with only slight improvements in overall survival (OS).”
Self-citationJurnal Review: Pengobatan Klinis Tumor Otak pada Orang Dewasa
Ghozali, M. (2021) · Jurnal Phi Jurnal Pendidikan Fisika dan Fisika Terapan · doi:10.22373/p-jpft.v2i1.8302 · Cited by 2
Togni, C., Rom, E., Burghardt, I., Roth, P., Rushing, E. J., Weller, M., & Gramatzki, D. (2022) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlac007 · Cited by 2
Self-citationShafizadeh, M., Jangholi, E., Rostami, M., Maroufi, S. F., Bereimipour, A., Majidi, S., Mohebbi, N., & Khoshnevisan, A. (2022) · Galen Medical Journal · doi:10.31661/gmj.v11i.1897 · Cited by 2
“Currently, the European society for medical oncology recommends concomitant chemo-radiotherapy and radiotherapy (a total of 60 Gy) along with daily intravenous temozolomide (TMZ) with maintenance TMZ implemented for 6–12 cycles (every 28 days) as the standard of care (SoC) for GBM after surgery [5].”
BackgroundChen, J., Qiu, H., Chen, R., Huang, J., Chen, L., Wan, J., Chen, Q., & Zhang, L. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/9547166 · Cited by 2
“However, after first-line treatment including surgery, radiotherapy, and temozolomide chemotherapy, the prognosis of GBM patients remains poor [10].”
BackgroundRetractedVery late complications of oncotherapy in glioblastoma patients: A case series
Kalita, O., Hrabálek, L., Halaj, M., Hok, P., Franc, D., Klementova, Y., Doležel, M., Čecháková, E., Sporikova, Z., Drábek, J., et al. (2021) · Biomedical Papers · doi:10.5507/bp.2021.012 · Cited by 2
Mallereau, C.-H., Baloglu, S., Chibbaro, S., Noblet, V., Todeschi, J., Noël, G., Gangi, A., de Mathelin, M., Proust, F., & Cébula, H. (2021) · Neurosurgical Review · doi:10.1007/s10143-021-01637-8 · Cited by 2
A miR-137-XIAP axis contributes to the sensitivity of TRAIL-induced cell death in glioblastoma
Geng, F., Yang, F., Liu, F., Zhao, J., Zhang, R., Hu, S., Zhang, J., & Zhang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.870034 · Cited by 2
Lv, G., Dong, Z., Zhao, Y., Ma, N., Jiang, X., Li, J., Wang, J., Wang, J., Zhang, W., Lin, X. H., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810561 · Cited by 2
“Although TMZ in 2005, bevacizumab in 2009 and tumor treating fields (TTF) in 2015 have been approved by the FDA to treat recurrent GBM, the effects of these treatments are not significant, and the prognosis is still very poor [20].”
BackgroundInfluentialJang, B., Park, A. J., & Kim, I. A. (2022) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-022-02003-4 · Cited by 2
“Otherwise, the reuse of current therapies is individualized according to the performance status, quality of life, and overall prognosis [7].”
BackgroundFresnais, M., Jung, I., Klein, U. B., Miller, A. K., Turcan, Ş., Haefeli, W. E., Burhenne, J., & Longuespée, R. (2023) · Cancers · doi:10.3390/cancers15030716 · Cited by 2
Zhao, F., Wang, X., Zhu, W., Zhao, D., Ye, C., Guo, Y., & Dou, Y. (2023) · Cancer Nanotechnology · doi:10.1186/s12645-023-00159-w · Cited by 2
Smrdel, U., Smrdel, A. C. Š., Podlešek, A., Vidmar, M. S., Kos, G., Markovic, J., Jereb, J., Knific, J., & Rus, T. (2023) · Croatian Medical Journal · doi:10.3325/cmj.2023.64.383 · Cited by 2
“The extent of resection was found to be an important prognostic factor, with resection and reduction being superior to biopsy (27,28).”
BackgroundPrognostic value of circulating short-length DNA fragments in unresected glioblastoma patients
Daban, A., Beaussire, L., Lévêque, É., Alexandru, C., Tennevet, I., Langlois, O., Veresezan, O., Marguet, F., Clatot, F., Fiore, F. D., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101897 · Cited by 2
“Glioblastoma is the most common primary brain tumors in adults, representing around 45 % to 50 % of newly-diagnosed cases among malignant tumors [1,2].”
BackgroundPositron emission tomography imaging of drug concentrations in the brain
Wen, P. Y. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab025 · Cited by 2
“7 applyparastyle "fig//caption/p[1]" parastyle "FigCapt"”
Self-citationExtended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?
Zhao, B., & Ma, W. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab110 · Cited by 2
Bagley, S. J., Binder, Z. A., Desai, A. S., Nasrallah, M. P., Maloney, E., Brem, S. S., Lustig, R. A., Kurtz, G. A., Alonso‐Basanta, M., Mohan, S., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2742648/v1 · Cited by 2
Kenchappa, R. S., Radnai, L., Young, E. J., Zarco, N., Lin, L., Dovas, A., Meyer, C. T., Haddock, A. N., Hall, A. B., Canoll, P., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.27.591399 · Cited by 2
Pan, S., Mirchia, K., Payne, E., Liu, S. J., Al-Adli, N. N., Peeran, Z., Shukla, P. D., Young, J. S., Gupta, R. K., Wu, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.01.601334 · Cited by 2
Self-citationMAT2a and AHCY inhibition disrupts antioxidant metabolism and reduces glioblastoma cell survivalPreprint
Rowland, E. C., D’Antuono, M., Jermakowicz, A. M., & Ayad, N. G. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.23.624981 · Cited by 2
Rabut, C., Daghlian, G. H., Barturen‐Larrea, P., Li, H., Bruegge, R. H. V., Jones, R. M., Malounda, D., Pinton, G., & Shapiro, M. G. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.22.629782 · Cited by 2
Hu, M., Weldy, A., Lovalvo, I., Akins, E. A., Jain, S., Chang, A. R., Sati, A., Lad, M., Lui, A., Rajidi, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.20.633978 · Cited by 2
Wang, F., Wu, X., Zhao, G., Huang, R., Yang, C., Bai, Y., Cao, W., Lu, Y., Lu, Y., Qiu, H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.25.696471 · Cited by 3
Self-citationAn elusive case of malignant optic nerve glioma with a suprasellar mass
Sun, M. J., Tran, A. Q., Dinkin, M., Kazim, M., & Tooley, A. A. (2022) · Orbit · doi:10.1080/01676830.2022.2101130 · Cited by 1
Zhao, H., Li, M., Liao, X., Liu, Y., Mo, X., Gong, M., & Liao, Y. (2022) · PubMed Central · doi:10.11817/j.issn.1672-7347.2022.210533 · Cited by 1
Mallik, M. K., Majumdar, K., & Mujtaba, S. (2023) · Brain Sciences · doi:10.3390/brainsci13020186 · Cited by 1
“has continued to be plagued by extremely poor survival [50,51].”
BackgroundSchipmann-Miletić, S., Sivakanesan, S., Rath, D., Brandal, P., Vik-Mo, E. O., Bjørås, M., Solheim, O. S., Ingebrigtsen, T., Sund, F., Bjerkvig, R., et al. (2023) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.22.0314 · Cited by 1
Sarıhan, S., ASLAN, G. G., Evrensel, T., & Kocaelı, H. (2023) · Uludağ Üniversitesi Tıp Fakültesi Dergisi · doi:10.32708/uutfd.1232437 · Cited by 1
Cheng, M., Pang, S., Wang, Z., Zhao, Y., & Li, W. (2023) · World Neurosurgery · doi:10.1016/j.wneu.2023.09.015 · Cited by 1
Ketogenic Diet in the Management of Glioblastomas: A Bibliometric Analysis
Brotis, A. G., Arvaniti, C. K., Kontou, M., Tsekouras, A., & Fountas, K. N. (2024) · Neuroglia · doi:10.3390/neuroglia5020005 · Cited by 1
“The standard of care in GBM management includes surgical resection, chemotherapy, and irradiation [4,5].”
BackgroundMethodDing, D., Gao, K., Zhang, X., & Hu, W. (2024) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2024.j033 · Cited by 1
Alhamood, M., Abbass, A., & Hasn, R. (2024) · Journal of Medical Case Reports · doi:10.1186/s13256-024-04679-w · Cited by 1
Gkasdaris, G., Berthiller, J., Guyotat, J., Jouanneau, E., Gallet, C., Meyronet, D., Thomas, L., Cartalat‐Carel, S., Seyve, A., Honnorat, J., et al. (2024) · Cancers · doi:10.3390/cancers16203465 · Cited by 1
“Despite multimodal management, glioblastoma progression is unfortunately observed almost systematically after a median interval of around 15 months following diagnosis, according to the most recent clinical data [6,7], and is generally local [8].”
BackgroundInfluentialOur clock is truly ticking—a qualitative study on patients’ experiences of tumor treating fields
Kastbom, L., Karlsson, M., Letter, N., Degsell, E., & Malmström, A. (2024) · Neuro-Oncology Practice · doi:10.1093/nop/npae102 · Cited by 1
Lau, A. C. K., Chan, B. L. H., Yeung, C.-K., Li, L., Chan, D. T., Lee, M. W. Y., Chan, T. K. T., Ho, J. M. K., Cheung, K. M., Tse, T. P. K., et al. (2024) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdae194 · Cited by 1
Immunocompetent murine glioblastoma stem-like cell models exhibiting distinct phenotypes
Kardani, K., Ghouse, S. M., Jabbar, M. A. D. A., Rajasubramanian, N., Gil, J. S., Stemmer-Rachamimov, A. O., Soda, Y., Martuza, R. L., Hara, T., Wakimoto, H., et al. (2024) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdae215 · Cited by 1
Laboratory-Engineered Glioblastoma Organoid Culture and Drug Screening
Wang, C., Stöffler, N., & Liu, H. (2025) · Journal of Visualized Experiments · doi:10.3791/67593 · Cited by 1
Kertmen, N., Kavgacı, G., Koc, I., SAĞOL, Ş. P., Işıkay, A. İ., & Yazıcı, G. (2025) · Oncology Letters · doi:10.3892/ol.2025.14892 · Cited by 1
“Despite aggres‑ sive initial treatment strategies, such as complete surgical removal and chemoradiotherapy, adult GBM often recurs shortly after initial treatment, indicating its high propensity for relapse (2).”
Characterizing long- and short-survival glioblastoma patients with FLT-PET/MRI and metabolomics
Axelsson, J., Björkblom, B., Asklund, T., Brandel, J., Larhed, S., Ringmar, G. M., Hedman, K., Riklund, K., Sjöberg, R. L., & Sandström, M. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf034 · Cited by 1
Hu, S. S., Gao, J., Wang, J., Liu, F., & Zeng, C. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101562 · Cited by 1
Optune in Glioblastoma: Revolutionizing Treatment with Tumor Treating Fields
Długozima, P., Mączewska, K., Hakało, D., Kozakiewicz, J., Kościelecki, K., Kalisz, A., Skorulska, I., Grzeszczuk, P., Grywińska, W. B., & Głowacka, A. (2025) · Quality in Sport · doi:10.12775/qs.2025.41.60190 · Cited by 1
Lopez, J. S., Haefliger, S., Plummer, R., Clément, P. M., Evans, T. R. J., Laubli, H. P., Roth, P., Kristeleit, R. S., Brazil, L., Tabatabai, G., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102165 · Cited by 1
“23,24 MTAs are among the most active cytotoxic anticancer drugs currently in use, inducing either polymerization or depolymerization of microtubules.”
Self-citationPD-L1 Clones and Their Relevance in Glioblastoma, IDH-Wildtype: A Comparative Analysis
Hendrych, M., Vana, F., Hermanová, M., Lakomý, R., Kazda, T., Matulova, K., Kopková, A., Jelinkova, M., Jančálek, R., Smrčka, M., et al. (2025) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-025-00245-y · Cited by 1
Khalaj, K., Tavakkol, E., Nunez, L. C., Jafarnia, J. L., Dono, A., Arevalo, O., Rodriguez, A. F., Zhu, J., Esquenazi, Y., Riascos, R., et al. (2025) · The Neuroradiology Journal · doi:10.1177/19714009251365745 · Cited by 1
Biomimetic hybrid vesicle nanoplatform with Pt-BaTiO3 for sonodynamic-immunotherapy of glioblastoma
Li, B., Zhao, L., Han, Z., Tang, Z., Qiu, J., Zhao, R., Feng, B., Zhang, Q., Wang, D., Gao, Z., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.167363 · Cited by 1
Pan, X.-H., Wang, N., He, Y., Su, J., & Gao, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1649414 · Cited by 1
Departments of Neurosurgery are Leaders in Highly Cited Glioblastoma Research
Tazhibi, M., Ramapriyan, R., Kotlarz, P. L., Steuart, S. J., Kalaw, A., Tazhibi, M., Carter, B. S., Chiocca, E. A., Nahed, B. V., Curry, W. T., et al. (2025) · Neurosurgery Open · doi:10.1227/neuprac.0000000000000170 · Cited by 1
Self-citationAboubechara, J. P., Liu, Y., Fiehn, O., Dahabiyeh, L. A., Fragoso, R. C., Lee, H. S., Riess, J. W., Hodeify, R. F., Bloch, O. G., & Aboud, O. (2025) · Metabolites · doi:10.3390/metabo15100673 · Cited by 1
“Despite aggressive treatment strategies involving surgery, radiation, and chemotherapy, glioblastoma invariably recurs [1].”
InfluentialKrucoff, M. O. (2025) · CNS Oncology · doi:10.1080/20450907.2025.2571341 · Cited by 1
Are conventional and hypofractionated chemoradiotherapy comparable in glioblastoma patients?
Guglielmo, F. C. D., Bonaparte, I., Davì, V., Guida, P., Ciliberti, M. P., Gregucci, F., Surgo, A., Caliandro, M., Carbonara, R., Giraldi, D., et al. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04107-5 · Cited by 1
Wach, J., Weber, F., Wende, T., Vychopen, M., Barrantes‐Freer, A., Pfahl, A., Köhler, H., & Güresir, E. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-05340-2 · Cited by 1
“Maximal safe resection remains the cornerstone of glioblastoma (GB) management, significantly impacting overall sur - vival (OS) [1, 2 ].”
Stitzlein, L. M., Nam, D., Hernandez, F. A., Patel, K. H., Poche, A., Ma, H., Impelman, K., Gumin, J., Wang, H., Wang, J., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf246 · Cited by 1
LINNDA: Lymphoma identification through neural network detection aid
Naser, P. V., Fischer, M., Maurer, M. C., Jazi, K. K., Ben-Salah, C., Bajwa, A. A., Jakobs, M., Jungk, C., Jungwirth, G., Jesser, J., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114153 · Cited by 1
“9,18 PCNSL, in contrast, is a type of non-Hodgkin lymphoma that occurs within the central nervous sys-tem.”
Colangelo, T., Saponaro, A. A., Mazzoccoli, G., Serviddio, G., & Villani, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262411826 · Cited by 1
“Currently, clinical practice relies on imaging modalities such as Gadolinium-enhanced magnetic resonance imaging (MRI), considered the gold standard for detecting intracranial tumors [37–39].”
MT-125: A glimpse of hope for glioblastoma patients
Roy, T. B., & Dokholyan, N. V. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100160 · Cited by 1
Necroptotic signaling orchestrates glioblastoma malignancy and potentiates temozolomide response
Li, Y., Qiu, Y., Gao, W., Geng, L., Wu, Z., Zhang, T., Pan, J., Lu, J., Zhang, D., Idris, A., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08377-3 · Cited by 1
“Standard therapy for glioma includes maximal safe surgical resection followed by radiochemotherapy [8, 9].”
Lučić, M., Djan, I., Šveljo, O., Lučić, S., Ivanov, O., Bjelan, M., & Ilic, D. (2025) · Vojnosanitetski pregled · doi:10.2298/vsp250525083l · Cited by 1
Mera, J. O., Montoya‐Gómez, A., Sevilla-Sánchez, M. J., Arboleda, A. M., Mosquera, M., & Jiménez–Charris, E. (2025) · Drug Development Research · doi:10.1002/ddr.70218 · Cited by 1
“Most GB patients have no family history of cancer, with only 5% of gliomas considered familial (Wen et al. 2020).”
Neoadjuvant PD1 blockade with laser interstitial thermal therapy for recurrent high-grade glioma
Suryadevara, C. M., Donaldson, H., Khan, H. A., Groff, K. J., Kim, C. D., Dogra, S., Gautreaux, J., Roberts, L. G., Young, M., Snuderl, M., et al. (2025) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2025.111823 · Cited by 1
Stem Cell‐Based Delivery of Immunomodulators for Overcoming Glioblastoma Immune Evasion
Ardah, M. T., Malathi, H., Maharana, L., Dhyani, A., Al-Hasnaawei, S., Singh‐Chauhan, A., Arora, V., Sharma, J., & Kumar‐Mishra, M. (2026) · Immunology · doi:10.1111/imm.70102 · Cited by 1
Hwang, M., Lee, J., Kim, S., Kim, M., Choi, S. H., Ahn, S. S., Lee, C., & Choi, K. S. (2026) · Scientific Reports · doi:10.1038/s41598-025-34134-9 · Cited by 1
“…months), which is consistent with previous study 36,37 , while the prognostic impact of MGMT methylation was most prominent after 18 months, reflecting its role in early treatment response, especially in relation to surgical tumor reduction and sensitivity to chemotherapy 38,39 As shown in Fig.”
Miranda, M. Á. E., Gutiérrez-Gutiérrez, D., Vargas-Valenciano, E., Ramos-Esquivel, A., Calvo-Molina, J., & Sahuquillo, J. (2026) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2025.0015 · Cited by 1
“These findings are consistent with previous evidence supporting the role of maximal resection and minimal residual tumor volume in enhancing survival in both high-grade and low-grade gliomas [5,55-58].”
Heugenhauser, J., Orth, W., Sarcletti, M., Iglseder, S., Kerschbaumer, J., Freyschlag, C. F., Nevinny‐Stickel, M., Grams, A. E., & Nowosielski, M. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdag032 · Cited by 1
Yu, Y., Li, Y., Wang, J., Zhu, Y.-J., Zhang, Z., Xiao, Z., Chen, Y., Qu, Y., Han, L., & Zhang, H. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00757-5 · Cited by 2
Wang, Z., Wu, H., Tan, X., Chen, Z., Chang, C., Zhang, D., Yang, Z., & Zhao, B. (2026) · Brain Research · doi:10.1016/j.brainres.2026.150231 · Cited by 1
Shan, D., Lu, C., Yu, H., Li, D., Cui, G., Zhou, Z., Zhu, Z., Siegelin, M. D., Liang, J., Zhang, Q., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218409 · Cited by 1
Investigation of the impact of resveratrol on sublethal-dose ALA-PDT in glioblastoma cells
Zhang, L., Zeng, Q., Kang, Z., Fang, S., Huang, T., Pohla, H., Wang, X., Rühm, A., & Sroka, R. C. (2026) · Photochemical & Photobiological Sciences · doi:10.1007/s43630-026-00877-1 · Cited by 1
Targeted therapies in adolescent and young adult patients with central nervous system tumors
Mullins, A., Bennett, J., Yeo, K. K., & Lim-Fat, M. J. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf043 · Cited by 1
“26 Similar to the LGG cohort, dabrafenib plus trametinib was well tolerated in the HGG cohort with no discontinuation due to side effects.”
Neto, V. A. D. F., Albuquerque, J. H. N., Melikian, L. D. C., Filho, J. C. D. A., Gondim, M. V. L., Rio, L. E. S., & Silva, H. R. D. S. E. (2026) · Neurosurgical Review · doi:10.1007/s10143-026-04229-6 · Cited by 1
Yan, X., Hu, J., Han, X., Xu, L., Zhou, L., He, J., Yang, F., Zhou, L., Niu, Y., Geng, M., et al. (2026) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2026.113430 · Cited by 1
Filimonova, E., Trukhachev, P. I., Kalinovsky, A., Perfil'ev, A. M., Соснов, А. О., & RZAEV, J. A. (2026) · Surgical Neurology International · doi:10.25259/sni_1267_2025 · Cited by 1
Wei, P., Jiang, J., Xiao, M., & Zhang, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1796708 · Cited by 1
“While delaying radiographic or clinical progression could be valuable by postponing neurological decline, reducing symptom burden, and potentially limiting corticosteroid exposure (56), such bene fi ts may not translate into prolonged survival.”
Impact of modern central nervous system radiation on multiple sclerosis relapse and progression
Zhao-Fleming, H. H., Ebner, D. K., Sperduto, W., Laughlin, B. S., Lachance, D. H., Breen, W. G., & Tobin, W. O. (2026) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2026.101176 · Cited by 1
“Ionizing radiation is the cornerstone of treatment of many malignancies, including CNS malignancies such as glioblastoma, systemic malignancies such as breast or lung carcinomas, as well as non-malignant disorders including meningioma and trigeminal neuralgia [1 – 3].”
Sabnis, N. A., Cooksey, L. C., Jayakumar, H., Mendez, M. M., Mathew, E., Petty, R. M., Ranjan, A. P., Colón-Pérez, L. M., Dickerman, R. D., Mathew, P. A., et al. (2026) · Brain Sciences · doi:10.3390/brainsci16050487 · Cited by 1
“The trial underscores the increasing relevance of immunotherapy in the GB treatment paradigm [264].”
Metadata
- Authors
- Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., Cloughesy, T. F., DeGroot, J. F., Galanis, E., Gilbert, M. R., Hegi, M. E., Horbinski, C., Huang, R. Y., Lassman, A. B., Le Rhun, E., Lim, M., Mehta, M. P., Mellinghoff, I. K., Minniti, G., Nathanson, D., Platten, M., Preusser, M., Roth, P., Sanson, M., Schiff, D., Short, S. C., Taphoorn, M. J. B., Tonn, J.-C., Tsang, J., Verhaak, R. G. W., von Deimling, A., Wick, W., Zadeh, G., Reardon, D. A., Aldape, K. D., & van den Bent, M. J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Zurich (CH)
- Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio, USA
- The Jackson Laboratory for Genomic Medicine (US)
- Yale University (US)
- University of California, San Francisco (US)
- University of California, Los Angeles (US)
- The University of Texas MD Anderson Cancer Center (US)
- Mayo Clinic (US)
- National Institutes of Health (US)
- Centre Hospitalier Universitaire Vaudois (CH)
- Northwestern University (US)
- NewYork–Presbyterian Hospital (US)
- University of Lille, Inserm, Neuro-oncology, General and Stereotaxic Neurosurgery service, University Hospital of Lille, Lille, France; Breast Cancer Department, Oscar Lambret Center, Lille, France and Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland
- Johns Hopkins University (US)
- Miami Cancer Institute, Miami, Florida, USA
- Memorial Sloan Kettering Cancer Center (US)
- University of Siena (IT)
- Heidelberg University (DE)
- Medical University of Vienna (AT)
- Centre National de la Recherche Scientifique (FR)
- University of Virginia (US)
- University of Leeds (GB)
- Leiden University Medical Center (NL)
- LMU Klinikum (DE)
- Neuropathology and Clinical Cooperation Unit Neuropathology, University Heidelberg and German Cancer Center, Heidelberg, Germany
- Princess Margaret Cancer Centre (CA)
- National Cancer Institute (US)
- Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
- Corresponding author
- Wen, Patrick Y
- Weller, Michael
- ORCID
- Wen, Patrick Y
- Weller, Michael
- Lee, Eudocia Quant
- Alexander, Brian M
- Barthel, Floris P
- Batchelor, Tracy T
- Bindra, Ranjit S
- Chang, Susan M
- Chiocca, E Antonio
- Cloughesy, Timothy F
- Galanis, Evanthia
- Gilbert, Mark R
- Hegi, Monika E
- Horbinski, Craig
- Huang, Raymond Y
- Lassman, Andrew B
- Lim, Michael
- Mehta, Minesh P
- Mellinghoff, Ingo K
- Minniti, Giuseppe
- Nathanson, David
- Platten, Michael
- Preusser, Matthias
- Roth, Patrick
- Sanson, Marc
- Schiff, David
- Short, Susan C
- Taphoorn, Martin J B
- Tonn, Joerg-Christian
- Tsang, Jonathan
- Verhaak, Roel G W
- Wick, Wolfgang
- Zadeh, Gelareh
- Reardon, David A
- Aldape, Kenneth D
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-04-24
- Volume
- 22
- Issue
- 8
- Pages
- 1073-1113
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- PMC
- PMC7594557
- OpenAlex
- W3020099303
- Cited by
- 1,168
- References
- 334
- Citations by year
- 2026: 166 · 2025: 215 · 2024: 242 · 2023: 204 · 2022: 194 · 2021: 118 · 2020: 28
- FWCI
- 71.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Neuro-Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- SERVAL (Université de Lausanne) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion, cc-by-nc)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- IRIS (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- JuSER (Forschungszentrum Jülich) (submittedVersion)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Funders
- University of Leeds
- National Institutes of Health (UL1TR001863)
- National Cancer Institute (P01CA069246, P30CA008748, P50CA211015, P30CA016672, P01CA163205)
- National Institute of Neurological Disorders and Stroke (R35NS105109)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- glioblastoma, IDH-wildtype glioblastoma, adult brain tumors, molecular pathogenesis, targeted therapy, DNA damage response, metabolic therapy, immunotherapy, viral therapy, treatment management
- MeSH terms
- Brain Neoplasms, Glioblastoma, Humans, Isocitrate Dehydrogenase, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Chemoradiotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
